NEW YORK, Jan.
29, 2019 /PRNewswire/ — At a gathering of institutional investors this morning, Atomic Capital and Agenus Inc (NASDAQ: AGEN), announced the launch of a groundbreaking digital securities offering enabling the direct participation of accredited investors in Agenus’ lead immuno-oncology asset.
The proceeds from the digital securities offering, the first conducted by a publicly-traded company, will go to fund product development through FDA approval and commercialization, of the asset, with returns to investors backed by future product sales.
“Atomic Capital is deeply committed to leveraging the transformative capabilities of Distributed Ledger Technology in the pursuit of our mission to make capital smarter.” said Alexander S.
Blum, CEO of Atomic Capital. “We are privileged to be working alongside Dr.
Armen and his remarkable team, bringing precision capital to precision medicine.”
Digital securities built on a distributed ledger use smart contracts to enforce compliance and investor protection while also providing access to secondary liquidity via 24/7 global markets.
“We are excited to be working with Atomic Capital, an innovator in emerging blockchain-based digital securities, in the launch of the first of its kind Biotech Electronic Security Token,” said Garo Armen, PhD Chairman and CEO of Agenus.
“We believe this unique instrument will pave the way for allowing targeted investment by any qualified investor in the development of therapeutic drugs and has the potential to transform how drug development is financed.”
Atomic Capital also announced this morning the launch of the digital securities offerings of two additional clients on their platform; a US-licensed, digital bank, and a blockchain-enabled digital AdTech company.
About Atomic Capital
Atomic Capital is a technology and financial group with a digital investment banking platform leveraging smart contracts and to automate the compliant offering, sale, and issuance of digital securities to investors.
How to Invest in Biotechs
Atomic Capital delivers the core technology, global relationships, and industry experience to bring growth capital to exceptional investments across the infrastructure, software, and life sciences sectors.
Atomic Capital is headquartered in New York City.
For more information, visit www.atomiccapital.io and follow on Twitter at @Atomic_Capital.
About Agenus Inc
Agenus is a clinical-stage immuno-oncology company focused on the discovery and development of therapies that engage the body’s immune system to fight cancer.
The Company’s vision is to expand the patient populations benefiting from cancer immunotherapy by pursuing combination approaches that leverage a broad repertoire of antibody therapeutics, proprietary cancer vaccine platforms, and adoptive cell therapies (through its AgenTus Therapeutics subsidiary). The Company is equipped with a suite of antibody discovery platforms and a state-of-the-art GMP manufacturing facility with the capacity to support early phase clinical programs.
Agenus is headquartered in Lexington, MA. For more information, please visit www.agenusbio.com and on twitter @agenus_bio.
Atomic Capital and its affiliates are licensed with LoHi Securities, A Registered Broker-Dealer, Member FINRA/SIPC, 1888 Sherman Street, Suite 770 Denver, CO 80203 USA.
720-465-5305. LoHi Securities and Atomic Capital, Inc.
are not affiliated entities.
SOURCE Atomic Capital